Compare BCPC & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCPC | GRFS |
|---|---|---|
| Founded | 1967 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.5B |
| IPO Year | 1995 | N/A |
| Metric | BCPC | GRFS |
|---|---|---|
| Price | $175.90 | $8.09 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $176.00 | $10.15 |
| AVG Volume (30 Days) | 179.3K | ★ 593.8K |
| Earning Date | 04-30-2026 | 07-28-2022 |
| Dividend Yield | 0.55% | ★ 1.75% |
| EPS Growth | ★ 20.87 | N/A |
| EPS | ★ 4.75 | N/A |
| Revenue | ★ $799,023,000.00 | N/A |
| Revenue This Year | $8.47 | $4.49 |
| Revenue Next Year | $4.89 | $6.42 |
| P/E Ratio | $36.71 | ★ $18.67 |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $139.17 | $6.90 |
| 52 Week High | $183.90 | $11.14 |
| Indicator | BCPC | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 44.92 |
| Support Level | $147.94 | $7.64 |
| Resistance Level | $177.88 | $8.88 |
| Average True Range (ATR) | 3.45 | 0.19 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 76.45 | 18.20 |
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.